[Sparfloxacin in combined therapy for pulmonary tuberculosis].
Efficacy and safety of the difluoroquinolone sparfloxacine used in combined therapy for drug-succeptible and drug-resistant pulmonary tuberculosis were studied. Clinical trials enrolled 60 patients with severe pulmonary tuberculosis. The most effective combinations of sparfloxacine and other antituberculous drugs were determined. Data on satisfactory tolerability of sparfloxacine used in various combinations of the main and reserve agents are presented.
Sokolova
G B
GB
Khaĭmenova
T Iu
TIu
Lazareva
Ia V
IaV
Khaĭmenov
A Ia
AIa
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D017484:Dermatitis, Phototoxic / Q000209:etiology; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D055815:Young Adult
D000995:Antitubercular Agents; D024841:Fluoroquinolones; C061363:sparfloxacin